Identify more evidence-based treatment options
We have different genomic profiling services which can satisfy individual patients' needs. Using genetic testing before cancer treatment can help you to develop a better treatment strategies for your patients. To understand which therapy bests suits your patient, it is important to understand the mechanism driving the growth of your patient's tumor. Since 300 to 400 genes in different cancer signaling pathways may be involved in this process, comprehensive genomic profiling services are required for thorough analysis. ACTOnco®+ is a comprehensive tumor genomic profiling service that covers more than 400 cancer-related genes to uncover the cancer mechanism of your patient and find the most appropriate matching targeted therapy based on a whole pathway analysis.
ACTDrug®+ is a tumor genetic test that precisely analyses carefully selected cancer-related genes with well-defined therapeutic implications, especially for patients with breast, lung and colorectal cancer.
ACTBRCA ™ detects germline and somatic mutations in the BRCA1/2 genes. The test is therefore capable to identify patients with breast, ovarian, prostate and pancreatic cancer that may benefit from targeted therapy by PARP inhibitors and informs about an inherited risk for developing those specific cancers.
If you would like to have a comprehensive evaluation of chemotherapy and targeted therapy choices for your patient, you may consider using our comprehensive genomic profiling service: ACTOnco®+.
If you would like to have an evaluation of targeted therapy choices for your patient, you may consider using our targeted genomic profiling service: ACTDrug ®+
If you would like to have an evaluation for specific drug choices for your patient, you may consider using our BRCA1/2 analyzing panel, ACTBRCA™